Facts about the Miraca Group
Established in 1950
The history of the Miraca Group dates back to the year 1950, when Fujizoki Pharmaceutical (later known as “Fujirebio”) was established.
Later in 1970, the Tokyo Special Reference Laboratories (later known as “SRL”) was established as a commercial laboratory that mainly provided esoteric testing services.
For over half a century, the Miraca Group has engaged in clinical diagnostic products manufacture and sales, as well as in the development of business that focuses on clinical testing contracts.
400 Million Tests
We conduct approx. 400 million tests each year.
At SRL, we conduct over 200,000 tests per day for hospitals and clinics across Japan, totaling nearly 400 million tests per year. This means that the number of tests our laboratory conducts in a single year is THREE times the entire population of Japan.
The world’s first company to successfully commercialize a serological test reagent for syphilis
In 1966, Fujizoki Pharmaceutical (later known as “Fujirebio”) successfully developed the world’s first commercialized serological test reagent for syphilis, and began sales of Treponema Pallidum Hemagglutination assay (TPHA).
At that time, the spread of syphilis was considered as a serious problem. This test kit was highly praised as it delivered a reliable diagnostic result easily without skilled technicians or laboratories equipped with special instruments.
Ever since then, we have provided high-quality diagnostic reagents and instruments to medical institutions and blood centers across the world focusing on infectious diseases and cancer.
First Robot in Japan
Japan’s first two-armed robot used in a testing laboratory
In 2010, SRL introduced a two-armed robot into the testing process for the first time among Japanese testing laboratories.
Using a robot to handle processes that were previously handled by human hands streamlines testing workflows, saves on labor, and improves testing quality due to the quality checks only possible via robot.
Percentage of dealings with major hospitals in Japan
Since our founding, SRL has specialized in esoteric testing that requires a higher level of technology, and has expanded its market share in mainly large hospitals.
To meet requests from physicians at university hospitals and national hospitals, SRL has maintained a high level of technical and academic expertise and a system for its services, and thus built trusted relationships with medical institutions as the top company for esoteric testing.
As a result, we currently deal with approximately 80% of large hospitals in Japan.*
*According to SRL research (Calculated based on the number of transactions with facilities that have 300 or more beds.)
25 years of the LUMIPULSE® series
Fujirebio’s main product is the LUMIPULSE® series, a fully automated chemiluminescent enzyme immunoassay system launched in 1992, which marks its 25th anniversary in 2017. The LUMIPULSE® series features an automated testing process which delivers highly sensitive testing by pairing the instrument with dedicated reagents.
In the LUMIPULSE® series, approximately 50 test items are currently available, with a focus on infectious diseases, tumor markers, and various hormones. Also, we offer models with various processing capabilities, providing the solutions that are optimally matched to the scale of your hospital or medical organization.
70% of the chromosome test share in Japan
SRL opened Gene Chromosome Analysis Center in 1995. This is the largest chromosomal testing center in Japan in terms of number of chromosoml test items, contracts, and technicians.
Currently SRL handles approximately 70% of all chromosome testing in Japan*, testing for congenital anomalies, leukemia, etc.
*According to SRL research (Rate calculated based on survey results from Japan Registered Clinical Laboratories Association for the number of tests conducted by SRL)
Providing products and services to over 100 countries
Utilizing business bases in and outside Japan, Miraca Group currently offers a wide range of products and services in over 100 countries.
Our subsidiary in the United States develops and produces world-class level cancer tests and provides raw materials for reagents.
Our subsidiary in Belgium develops and produces reagents for use in the realm of Alzheimer’s Disease, a disease that is said to affect 46 million people* worldwide.
*According to research in the World Alzheimer Report 2015 by Alzheimer’s Disease International (ADI).